NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis $0.38 +0.01 (+2.15%) Closing price 04:00 PM EasternExtended Trading$0.38 0.00 (-0.29%) As of 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adial Pharmaceuticals Stock (NASDAQ:ADIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Adial Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.36▼$0.3950-Day Range$0.23▼$0.6352-Week Range$0.22▼$1.30Volume632,304 shsAverage Volume4.09 million shsMarket Capitalization$8.30 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingBuy Company Overview Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia. Read More Adial Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreADIL MarketRank™: Adial Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAdial Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAdial Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Adial Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adial Pharmaceuticals are expected to grow in the coming year, from ($1.53) to ($1.33) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 1.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.82% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently increased by 919.93%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.82% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently increased by 919.93%, indicating that investor sentiment is decreasing significantly. News and Social Media1.9 / 5News Sentiment0.35 News SentimentAdial Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Adial Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 6 people have searched for ADIL on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.26% of the stock of Adial Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 16.41% of the stock of Adial Pharmaceuticals is held by institutions.Read more about Adial Pharmaceuticals' insider trading history. Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ADIL Stock News HeadlinesAdial Hails Senate Moves on TrialsAugust 20 at 4:24 PM | baystreet.caAdial Pharmaceuticals Applauds U.S. Senate Support for Expanding Clinical Trial Endpoints in Alcohol Use Disorder TreatmentsAugust 20 at 8:51 AM | quiverquant.comQCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just discovered a new way to do it with 10X less money.August 22 at 2:00 AM | Investors Alley (Ad)Short Interest in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Expands By 919.9%August 15, 2025 | americanbankingnews.comAdial Pharmaceuticals expects cash to fund operations into Q2 of 2026August 15, 2025 | msn.comAdial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business UpdateAugust 14, 2025 | globenewswire.comAdial Pharmaceuticals (ADIL) Projected to Post Quarterly Earnings on TuesdayAugust 11, 2025 | americanbankingnews.comAdial Pharmaceuticals Enters New Sales AgreementAugust 9, 2025 | theglobeandmail.comSee More Headlines ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed this year? Adial Pharmaceuticals' stock was trading at $1.01 on January 1st, 2025. Since then, ADIL shares have decreased by 62.4% and is now trading at $0.3801. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its quarterly earnings results on Wednesday, August, 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.04. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals shares reverse split before market open on Monday, August 7th 2023.The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering (IPO) on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), CymaBay Therapeutics (CBAY), Arista Networks (ANET) and GE Aerospace (GE). Company Calendar Last Earnings8/13/2025Today8/22/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADIL CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Adial Pharmaceuticals$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+2,004.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-191.31% Return on Assets-153.59% Debt Debt-to-Equity RatioN/A Current Ratio5.02 Quick Ratio5.02 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.26 per share Price / Book1.46Miscellaneous Outstanding Shares21,830,000Free Float20,898,000Market Cap$8.30 million OptionableNo Data Beta1.00 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ADIL) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredCould This Be the End of Retirement Worries?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.